Cereno Scientific Ab Class B · OMXSTO:CRNO_B
Cereno Scientific Ab Class B — Investor Presentation (September 2022)
21 slides from Cereno Scientific Ab Class B's investor presentation, September 2022
Slide 1: Cereno Scientific
Cereno Scientific Innovative treatments in common and rare cardiovascular disease September 2022
Slide 2: Disclaimer
Disclaimer This presentation has been prepared and produced by Cereno Scientific AB (publ) (“Cereno Scientific”) solely for Cereno Scientific’s investor presentation and may not be used for any other purpose. Unless otherwise stated, Cereno Scientific is the source for all data contained in this pre
Slide 3: More than 200 million people at high risk of a cardiovascular event
More than 200 million people in the world today are at high risk of having a cardiovascular event ”Previously we used to work ourselves to death, today we rest ourselves to death while eating easily available food” Inactivity = Smoking 3
Slide 4: Cereno develops novel drugs for common and rare cardiovascular diseases
Cereno develops novel drugs to transform treatments for common and rare cardiovascular diseases Introducing Lead program CS1 currently in US Epigenetic modulation through Phase II in PAH with strong rationale HDAC inhibition with disease and supportive data: modifying potential First patient randomi
Slide 5: Cereno Scientific to transform the treatments of cardiovascular disease
Cereno Scientific to transform the treatments of cardiovascular disease Pioneering clinical- Strong scientific Innovative drug Uniquely positioned stage biotech leadership development to make an impact company on common and • Thought leaders • Epigenetic HDACis rare CVD • Discovery of the in CVD • C
Slide 6: Promising programs with potential to transform the CVD treatment landscape
Promising programs with potential to transform the CVD treatment landscape Program Indication Discovery Preclinical Phase I Phase II Phase III Next milestone Phase II top-line CS1 PAH HDACi with epigenetic effects data: Q1, 2023 HDACi with Phase I IND CS014 CVD epigenetic effects submission: 2023 Pr
Slide 7: HDACi game-changing with epigenetic modulation of cardiovascular disease
HDACi game-changing with epigenetic modulation of cardiovascular disease CS1 and preclinical CS014 acts as epigenetic modulators • Epigenetic modulation is the alteration of gene expression without altering genetic material. • Epigenetic changes play a significant role in the pathogenesis of many CV
Slide 8: Phase II CS1: Focus on developing a disease-modifying treatment for PAH
Phase II CS1: Focus on developing a disease-modifying treatment for the fatal rare disease PAH CS1’s multi-fold efficacy, all relevant for PAH CS1 is a new advanced reformulation and acts as an epigenetic modulator Pulmonary pressure-reduction • Proven good safety and tolerability in Phase I study.
Slide 9: CS1 Phase II study aims to evaluate safety, tolerability and exploratory efficacy in PAH
CS1 Phase II study aims to evaluate safety, tolerability and exploratory efficacy in PAH • Primary endpoint: Safety and tolerability. Study status • Other variables including all standard efficacy endpoints for this • First site activated: 14 Mar 2022 patient group (6MWT etc.), a calculated validate
Slide 10: Leaving a mark in the medical community through abstracts accepted at top congresses
Leaving a mark in the medical community through abstracts accepted at top congresses June 9-12, 2022 June, 22-26 2022 August 26-29, 2022 October 16-19, 2022 CS585 is a first-in-class Investigation of efficacy, CS014 is a novel HDAC An innovative phase 2 clinical compound targeting the IP safety and
Slide 11: Promising programs with potential to transform the CVD treatment landscape
Promising programs with potential to transform the CVD treatment landscape Program Indication Discovery Preclinical Phase I Phase II Phase III Next milestone Phase II top-line CS1 PAH HDACi with epigenetic effects data: Q1, 2023 HDACi with Phase I IND CS014 CVD epigenetic effects submission: 2023 Pr
Slide 12: Most deaths worldwide are caused by cardiovascular disease
Most deaths worldwide are caused by cardiovascular disease Cardiovascular disease (CVD) is a group of disorders of the heart and blood vessels. WHY? Most CVD complications happen because of thrombus formation – 22.2 million people blood clots obstructing the are expected to die annually due to CVD b
Slide 13: Current anti-thrombosis treatment involves the risk of serious bleedings
Current anti-thrombosis/blood thinning treatment involves the risk of serious bleedings Waran Brilique Xarelto Trombyl Persantin Plavix Eliquis Depot Pradaxa Efient Systemic inhibition of coagulation/platelet function Increased risk of bleeding Insufficient preventive effect Need for new preventive
Slide 14: CS585 inhibits platelet clot formation following injury
CS585 inhibits platelet clot formation following injury and represents a new approach for prevention of thrombosis without increased bleeding Vehicle control CS585 3mg/kg CS585 6mg/kg 14
Slide 15: CS014 developed as an HDAC inhibitor to inhibit platelet clot formation
CS014 developed as an HDAC inhibitor with the ability to inhibit platelet clot formation following vascular injury Control *** 9000 CS014 100 mg/kg Pre-injury 1 min 2 min 3 min 8000 7000 Platelet MFI 6000 Saline 5000 control 4000 3000 2000 1000 0 0 1 2 3 4 CS014 Time (mins) 100 mg/kg 600 Control ***
Slide 16: Cereno will enter one of the largest pharmaceutical markets
Cereno will enter one of the largest pharmaceutical markets with a profile which will impact thrombosis management NOACs/ Warfarin CS585 CS1, CS014 Antiplatelets Dose monitoring not required Required Anti-thrombotic efficacy Lower risk of Increased Increased bleeding bleeding bleeding Not Not Not ¤
Slide 17: Promising programs with potential to transform the CVD treatment landscape
Promising programs with potential to transform the CVD treatment landscape Program Indication Discovery Preclinical Phase I Phase II Phase III Next milestone Phase II top-line CS1 PAH HDACi with epigenetic effects data: Q1, 2023 HDACi with Phase I IND CS014 CVD epigenetic effects submission: 2023 Pr
Slide 18: Cardiovascular disease equals exorbitant costs for patients, families and society
Cardiovascular disease equals exorbitant costs for patients, their families and society • Common and rare CVDs result in significant markets Societal annual cost of CVD due to their mortality threat and adverse effect on the quality of life of patients These numbers are • The global anti-thrombotic
Slide 19: Full steam ahead in 2022
Full steam ahead in 2022 Key 2022 achievements and upcoming milestones ü CS585 and CS014 nominated in Q2 as CDs for further development towards IND submission for clinical programs ü CS585 thrombosis data (prevention of thrombosis without increased risk of bleeding) accepted for EHA June 2022 ü CS01
Slide 20: Cereno's strategy to provide value for patients and stakeholders
Cereno’s strategy to provide value for patients and stakeholders Cereno’s key objectives 2024 Utilizing the project portfolio’s full potential on 2023 profitable markets within cardiovascular disease. 2022 Clinical phase Clinical phase Initiated Phase IIb/III study in PAH with CS1 Topline data Phase
Slide 21: Cereno Scientific is a clinical stage biotech company within cardiovascular diseases
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epige
Cereno Scientific — Investor Presentation (September 2022) on 6ix